ArticleBritish journal of pharmacology2008
Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia.
Article in British journal of pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 59 citations in OpenAlex.
- Crosstalk of thioredoxin system and programmed cell death: from pathophysiology to novel therapy.Redox biology · 2026Review
- Translational toxicology of metal(loid) species: linking their bioinorganic chemistry in the bloodstream to organ damage onset.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024Review
- Gold Nanoclusters as Nanoantibiotic Auranofin Analogues.Advanced healthcare materials · 2022Article
- Comprehensive chemical proteomics analyses reveal that the new TRi-1 and TRi-2 compounds are more specific thioredoxin reductase 1 inhibitors than auranofin.Redox biology · 2021Article
- Proteogenomic landscape of uterine leiomyomas from hereditary leiomyomatosis and renal cell cancer patients.Scientific reports · 2021Article
- Article
- Mechanistic Insights Into the Anticancer Properties of the Auranofin Analog Au(PEtFrontiers in chemistry · 2020Article
- Functional Profiling Identifies Determinants of Arsenic Trioxide Cellular Toxicity.Toxicological sciences : an official journal of the Society of Toxicology · 2019Article
- Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy.Science translational medicine · 2018Article
- Selection and characterization of a human ovarian cancer cell line resistant to auranofin.Oncotarget · 2017Article
- Selenite promotes all-trans retinoic acid-induced maturation of acute promyelocytic leukemia cells.Oncotarget · 2016Article
- EM23, a natural sesquiterpene lactone, targets thioredoxin reductase to activate JNK and cell death pathways in human cervical cancer cells.Oncotarget · 2016Article
- Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells.Oncotarget · 2016Article
- Leishmania donovani Encodes a Functional Selenocysteinyl-tRNA Synthase.The Journal of biological chemistry · 2016Article
- The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2D.The Journal of biological chemistry · 2014Article
- The biological activity of auranofin: implications for novel treatment of diseases.Inflammopharmacology · 2012Review
- A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target.Nature medicine · 2012Article
- Exposure to silver nanoparticles inhibits selenoprotein synthesis and the activity of thioredoxin reductase.Environmental health perspectives · 2012Article
- Anticancer activity of metal complexes: involvement of redox processes.Antioxidants & redox signaling · 2011Review
- Targeting selenium metabolism and selenoproteins: novel avenues for drug discovery.Metallomics : integrated biometal science · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
background and purposeArsenicals have been used medicinally for decades to treat both infectious disease and cancer. Arsenic trioxide (As2O3) is effective for treatment of acute promyelocytic leukaemia (APL), yet the mechanism of action of this drug is still widely debated. Recently, As2O3 was shown to inhibit the activity of the selenoenzyme thioredoxin reductase (TrxR). TrxR has been proposed to be required for selenium metabolism. The effect of inhibitors of TrxR on selenium metabolism has yet to be assessed. This study aims to determine whether chemotherapeutics that target selenocysteine within selenoenzymes may also affect the metabolism of selenium. EXPERIMENTAL APPROACH: A lung cell line, A549, was used to assess the effect of TrxR inhibitors on selenium metabolism, using 75Se-selenite. The level of mRNA encoding cytosolic TrxR (TrxR1) was determined using real-time reverse transcriptase-PCR. TrxR activity was determined in whole-cell extracts. KEY
resultsExposure of cells to As2O3, arsenite or auranofin led to a concentration-dependent reduction of selenium metabolism into selenoproteins. Knockdown of TrxR1, using small inhibitory RNA, did not affect selenium metabolism. Exposure of cells to monomethylarsonic acid, a potent inhibitor of TrxR, did not alter selenium metabolism but did inhibit enzyme activity. CONCLUSIONS AND IMPLICATIONS: As2O3 and auranofin block the metabolism of selenium in A549 cells. Because As2O3 is used to treat APL, our findings may reveal the mechanism of this therapeutic action and lead to further research targeting selenium metabolism to find novel chemotherapeutic agents for the treatment of APL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.